Health News covers regulatory and clinical developments as they are issued: approvals, recalls, safety communications and guideline revisions. Each report names the issuing authority, describes who is affected, and states what action a reader should take. Filed quickly, and corrected openly whenever facts change.
Drug approvals, product recalls, safety advisories and revised clinical guidance, written so a reader knows immediately whether it applies to them.
The CDC's March 2024 guidance replaced the five-day COVID isolation period with symptom-based advice for all respiratory viruses — a change built on population immunity, not on milder viruses.
Written by Grace Mensah
New federal data show a rising share of incoming kindergartners entered school this year without required vaccinations, as measles activity climbs nationwide.
Written by Grace Mensah
Forty-eight human cases were reported by June 30, about five times the usual figure, and counts reached 143 through August 4, per CDC-based data.
Written by Grace Mensah
CDC surveillance recorded 2,465 confirmed cases by August 6, with 94 percent tied to outbreaks and hospitalization in about 7 percent of cases.
Written by Grace Mensah
A July 14 health notice tied the seasonal surge to 34 states and 141 hospitalizations, with a food source still under FDA investigation.
Written by Grace Mensah
Otsuka's centanafadine, the first approved norepinephrine, dopamine, and serotonin reuptake inhibitor, is cleared for patients 6 and older.
Written by Grace Mensah
The agency cleared Jideytro on July 22, 2026 for patients whose ROS1-positive non-small cell lung cancer advanced on a prior ROS1 inhibitor.
Written by Grace Mensah
Merck's once-daily Lipfendra (enlicitide) cut LDL cholesterol by nearly 60 percent in trials and offers an alternative to injections.
Written by Grace Mensah
The second IGF-1R antibody cleared for the condition extends targeted treatment to patients in both active and chronic stages, its developer says.
Written by Grace Mensah
Xocova (ensitrelvir) cut the risk of symptomatic infection by about 67 percent in the SCORPIO-PEP trial and is cleared for people 12 and older.
Written by Grace Mensah